Rhizen receives USFDA orphan drug designation for cancer drug

The US Food and Drug Administration (USFDA) has granted orphan drug
designation for Tenalisib (RP6530) for the treatment of patients with
peripheral T-cell lymphoma (PTCL), Alembic Pharmaceuticals said in a
BSE filing.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/rhizen-receives-usfda-orphan-drug-designation-for-cancer-drug/articleshow/80401115.cms

Comments

Popular posts from this blog

Freshers Job: Life Sciences Associate – Claims Vacancy at Genpact

Piramal Pharma Program Associate Vacancy Available